Agonist News and Research

RSS

Specialty asthma care no benefit to adherence in underserved children

Results of a study of underserved children with asthma in the USA suggest that they may be losing out on the benefits of specialty care.

20 Sep 2013

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo.

18 Sep 2013

Neuroscientists honored for research into brain's reward and decision-making systems

Maximum reward, minimum punishment: these are the maxims humans and animals often apply when making decisions. A network of nerve cells in the brain conveys gratification.

12 Sep 2013

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.

11 Sep 2013

Rhythm Awarded $1.35M From Michael J. Fox Foundation

...

10 Sep 2013

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research has awarded a $1.35 million research grant to Rhythm to help fund a Phase 2 clinical trial of RM-131, the company's novel ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease.

10 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

9 Sep 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

Osteoarthritis is an extremely common condition affecting about 8 million people in the UK. The elderly are particularly susceptible, with up to 45% of people over 65 years, having the disease.

14 Aug 2013

Using the immune system to control cancer: an interview with Dr. Jedd Wolchok, MD, PhD, Ludwig Center at MSKCC

Cancer immunotherapy aims to recruit a patient’s immune system to recognize cancer as foreign and dangerous and to remove it from the body, as it would an infection.

1 Aug 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13.

31 Jul 2013

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Sosei Group Corporation confirms the information released by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

29 Jul 2013

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

ADT increases risk of kidney injury in patients with prostate cancer

In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy (ADT) was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of ADTs, according to a study in the July 17 issue of JAMA.

17 Jul 2013

Actavis receives FDA approval for Opana ER tablets

Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-release Tablets, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg.

15 Jul 2013

Protein in liver plays a crucial role in mice's pregnancy and human menstrual cycle

A protein first shown to function in the liver plays a crucial role in pregnancy in mice and has a key role in the human menstrual cycle, according to researchers at the University of Montreal. Mice that were genetically engineered not to produce the liver receptor homolog-1 (Lrh-1) molecule were unable to create the uterine conditions necessary for establishing and sustaining pregnancy, resulting in the formation of defective placentas.

1 Jul 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Agonist News and Research

Specialty asthma care no benefit to adherence in underserved children

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Neuroscientists honored for research into brain's reward and decision-making systems

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Rhythm Awarded $1.35M From Michael J. Fox Foundation

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Patients with COPD show improvements in lung function with olodaterol

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

Using the immune system to control cancer: an interview with Dr. Jedd Wolchok, MD, PhD, Ludwig Center at MSKCC

Naurex receives new U.S. patent for its lead compound, GLYX-13

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

ADT increases risk of kidney injury in patients with prostate cancer

Actavis receives FDA approval for Opana ER tablets

Protein in liver plays a crucial role in mice's pregnancy and human menstrual cycle

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News